Leonard M. Klein

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Jeff P. Sharman, Michael Hawkins, Kathryn S. Kolibaba et al. · Blood · 2015 · 181 citations · Full text

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

Robert M. Jotte, Paul Conkling, Craig H. Reynolds et al. · Journal of Clinical Oncology · 2010 · 172 citations

Iatrogenic superior vena cava syndrome. A new entity

Marcelle Bertrand, Cary A. Presant, Leonard M. Klein et al. · Cancer · 1984 · 78 citations

Hickman Catheter, Central Venous Catheter, Venous Disease +12